The abstract is read at the publisher; the summary is JClub's.
In a matched cohort of 416 liver-transplant recipients with hepatocellular carcinoma initially beyond the Milan criteria, ICI-based multimodal downstaging improved overall survival (median 4.57 vs 2.53 years).
- Why it matters: Downstaging with immune checkpoint inhibitors before transplant is used to improve tumor control, but its links to posttransplant recurrence, survival, and acute rejection are still uncertain.
- What they did: This multicenter retrospective study in China (8 high-volume centers; Jan 2019–Dec 2024) used propensity score matching to compare ICI-based multimodal pretransplant therapy versus non-ICI therapy, then analyzed OS, RFS, recurrence, and 90-day acute rejection.
- The result: ICI-based multimodal therapy was associated with better OS (HR 0.63) and RFS (HR 0.59) and lower posttransplant recurrence risk (subdistribution HR 0.54), but acute rejection within 90 days was higher (16.3% vs 8.2%).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.